AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

AbbVie’s stock danced a volatile jig on June 20th, teasing both bulls and bears before landing barely changed at $185.30. The ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

AbbVie’s migraine drug Atogepant just cleared a major Phase 3 hurdle, and it’s got Wall Street rubbing its temples—in ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Health and Human Services Secretary Robert F. Kennedy Jr. wants to make it harder and more expensive for drug companies to advertise to patients.

Shares of AbbVie Inc. ABBV slid 2.82% to $185.48 Tuesday, on what proved to be an all-around poor trading session for the ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He’s long wanted to ...

The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...